Table 2.
Cancer incidence and mortality in carriers of t(11;22)(q23;q11) translocations
| Incidence | Mortality | ||||||
|---|---|---|---|---|---|---|---|
| ICD‐9 code | Cancer site | No. | SIR (95% CI) | AER | No. | SMR (95% CI) | AER |
| 140–171, 173–208 | All malignant neoplasmsa | 22 | 1.56 (0.98–2.36) | 241.0 | 9 | 1.44 (0.66–2.74) | 81.3 |
| 150 | Oesophagus | 1 | 3.18 (0.08–17.7) | 20.9 | 0 | 0 (0–12.8) | −8.5 |
| 153–154 | Colon and rectum | 1 | 0.64 (0.02–3.54) | −17.5 | 0 | 0 (0–6.11) | −17.7 |
| 162 | Lung | 4 | 2.35 (0.64–6.01) | 70.1 | 3 | 2.08 (0.43–6.09) | 45.9 |
| 163 | Pleura | 1 | 11.1 (0.28–62.0) | 27.8 | 0 | 0 (0–129.4) | −0.84 |
| 174–175, 233.0 | Breast, invasive or in situ | 12 | 3.72 (1.92–6.49) ** | 268.2 | 3 | 4.82 (0.99–14.1) | 70.0 |
| 174, 175 | Breast, invasive | 8 | 2.74 (1.18–5.40) * | 155.0 | 3 | 4.82 (0.99–14.1) | 69.9 |
| 233.0 | Breast, in situ | 4 | 13.0 (3.55–33.4) ** | 112.9 | 0 | 0 (0–∞) | 0 |
| 179,182 | Corpus uteri | 2 | 5.55 (0.67–20.1) | 81.4 | 0 | 0 (0–54.6) | −3.2 |
| 185 | Prostate | 1 | 0.69 (0.02–3.87) | −35.0 | 0 | 0 (0–13.4) | −21.0 |
| 189 | Kidney and ureter | 1 | 2.70 (0.07–15.1) | 19.2 | 0 | 0 (0–24.9) | −4.4 |
| 200, 202 | Non‐Hodgkin lymphoma | 1 | 1.93 (0.05–10.8) | 14.7 | 1 | 5.41 (0.14–30.1) | 24.0 |
| 204–8 | Leukaemia | 1 | 3.15 (0.08–17.6) | 20.8 | 0 | 0 (0–22.3) | −4.9 |
| 191, 192, 225, 237.5, 237.6, 237.9, 239.6 | Nervous system, including benign | 0 | 0 (0–8.91) | −12.6 | 1 | 4.34 (0.11–24.2) | 22.6 |
| 196.0–199.1 | Unknown primary site | 0 | 0 (0–8.62) | −13.1 | 1 | 1.96 (0.05–10.9) | 14.4 |
Abbreviations: AER, absolute excess rate; CI, confidence interval; ICD, International Statistical Classification of Diseases, 9th revision;10 SIR, standardised incidence ratio; SMR, standardised mortality ratio.
p < 0.05.
p < 0.001.
The category ‘All malignant neoplasms’ included neoplasms classified as malignant according to the ICD revision 9,10 excluding non‐melanoma skin cancer because it is under‐ ascertained by the cancer registries.23 Analyses by cancer site included registrations coded to malignant, with the exception that in situ breast cancers and non‐malignant nervous system tumours were included where stated. 1 malignancy of ill‐defined site is not listed individually in the table.